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MxA gene expression is known to be regulated tightly and exclusively by type I interferons
(IFNs). The kinetics of MxA gene expression was analyzed in peripheral blood mononuclear
cells from 11 healthy volunteers vaccinated with the 17-D strain of yellow fever virus. A reliable
induction of MxA RNA and MxA protein was found in the absence of easily detectable serum
IFN activity. Thus, steady-state MxA RNA levels were elevated 8- to 30-fold above prevaccina-
tion levels on day 5 after vaccination. The average increase of MxA protein was --50-fold. In
contrast, no induction of MxA RNA or MxA protein was detectable in 3 similarly vaccinated
controls who were immune because of previous vaccinations. The IFN marker 2'-5'-oligoadeny-
late (2-5A) synthetase known to react to both type I and type II IFNs showed a similar response
but did not differentiate equally well between nonimmune and immune vaccinees. P2-micro-
globulin and neopterin reacted poorly, remaining at low levels within the normal range. These
results demonstrate that MxA gene expression is a good marker for detecting minute quantities
of biologically active type I IFN during viral infections.
Interferons (IFNs) are produced in response to viral infec-
tion and contribute to host defense by establishing an anti-
viral state in target cells [I]. Viruses induce predominantly
two classes of IFNs, namely IFN-a and IFN-{1, collectively
called type I IFNs [2]. It is not always possible, however, to
detect circulating type I IFNs in the serum of patients most
likely because type I IFNs are produced early in infection
and may no longer be present in later serum samples or may
not be formed in detectable quantities. For example, serum
IFN is not usually found in patients with acute viral hepatitis
[3, 4], although IFN-induced changes occur in the liver and
are suggestive oflocal IFN production and action [5]. There-
fore, more reliable alternatives to direct serum IFN measure-
ments are needed.
Several assays have been developed that are based on the
capacity of IFNs to induce expression of IFN-responsive
genes in peripheral blood mononuclear cells (PBMC). In-
creased levels of an IFN-induced gene product indicate that
the cells have been exposed to IFN in vivo and are respond-
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ing to it. One of the most widely used assays measures the
induction ofan intracellular enzyme, 2',5'-oligoadenylate (2-
SA) synthetase [6-8]. This enzyme assay is considered to be
more sensitive than IFN measurements in serum [6] and has
the additional advantage that elevated enzyme activities re-
main detectable long after IFN has disappeared from the
blood [9]. Other tests measure p68 protein kinase, indolea-
mine 2,3-dioxygenase or guanylate binding proteins in
PBMC [10-12], or determine secreted products such as {12-
microglobulin in serum [13] or neopterin in urine [14].
These tests indicate elevated activities not only of type I IFN
but also oftype II ('Y) IFN that is produced by T lymphocytes
in the course of an immune reaction [2].
An exception is the human MxA protein, which qualifies
as a specific biochemical marker for the action of IFN-a and
IFN-{1 [15, 16]. The human MxA protein is a OTPase with
antiviral activity against orthomyxoviruses and certain other
negative-strand RNA viruses [17-20]. MxA gene expression
in human cells is tightly and specifically regulated by type I
IFNs[15, 16]. The specificity and dose response of MxA
expression in cell culture have been well established [15, 16,
21, 22]. The MxA gene in PBMC does not respond to tumor
necrosis factor or to a number of interleukins and growth
factors and shows only a minimal response to IFN-'Y, which
seems to act indirectly via IFN-a/{1 [15, 16]. Immunoblot
assays have been used to monitor MxA protein expression
during IFN-a treatment ofcancer patients [23, 24] or to dem-
onstrate the presence ofMxA protein in PBMC from patients
with diseases in which acid-labile serum IFN-a seems to play
a role [25, 26]. However, the kinetics of MxA gene expres-
sion in vivo during an acute viral infection has not previously
been established.
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Here, we analyzed MxA RNA and protein expression in
the course ofa self-limiting viral infection and compared the
usefulness of MxA as a marker for endogenous type I IFN
with that of various classic IFN markers.
Materials and Methods
Vaccination and determination ofantibody response. The 17-
D strain of yellow fever virus (YFV; Robert Koch Institut, Ber-
lin) was used for standard subcutaneous vaccination. Antibodies
to YFV were determined by hemagglutination inhibition at the
Institut fur Tropenmedizin (Hamburg, Germany). Three per-
sons known to have been previously vaccinated served as im-
mune controls.
Isolation ofplasma and PBMC. Venous blood samples con-
taining EDTA as anticoagulant were processed within 1 h of
drawing. Plasma was obtained by mild centrifugation and was
frozen at -70°C. PBMC isolated by Ficoll-Paque gradient cen-
trifugation (Pharmacia, Freiburg) were washed twice in PBS
and dispensed into aliquots of 2.5 and 5 X 106 cells. The cells
were then pelleted in Eppendorf tubes (Eppendorf-Netheler-
Hinz, Hamburg), shock-frozen in dry ice/ethanol, and stored
at -70°e.
IFN assays. Serum type I IFN activity was determined in a
bioassay as described by Rubinstein et al. [27] using Madin-
Darby bovine kidney cells and vesicular stomatitis virus. The
assay was calibrated against National Institutes of Health (Be-
thesda, MD) IFN-a standard G023-90 1-527. IFN-a2a concen-
trations in plasma samples were determined in the laboratory of
U. Elsasser (Institut fur Immunbiologie, Freiburg), by EIA
(Hoffmann-La Roche, Grenzach-Wyhlen, Germany).
The MxR assay was done exactly as described [28]. Vero Mx
13 cells (gift of C. Weissmann, Institute of Molecular Biology I,
University of Zurich, Switzerland) were grown to confluency in
Dulbecco's MEM supplemented by 10% heat-inactivated fetal
bovine serum and I mg/mL G418. The cells were then seeded
into six-well plates (Costar/Tecnomara, Fernwald, Germany) at
a density of 106 cells per well (3.5-cm diameter). After 24 h, the
cells were washed with PBS, and I mL ofmedium containing 5%
of the serum to be assayed was added. Aliquots of this medium
were frozen immediately after addition to the cells and after a
24-h incubation period. Human growth hormone (hGH) con-
tent of the aliquots was measured by RIA (Cis/Bio Interna-
tional, Dreieich, Germany). The amount ofhGH that had been
produced within 24 h was calculated by subtracting the hGH
concentration of the first aliquot from that of the second. IFN
standards (IFN-a2a, Roferon: Hoffmann-La Roche), which
were included, allowed the estimation of serum IFN concentra-
tions corresponding to hGH production.
RNA isolation and analysis. Total cellular RNA was isolated
from PBMC as described by Chomcynski and Sacchi [29].
Briefly, pellets of 5 X 106 PBMC were resuspended by sharp
vortexing in lysis buffer containing guanidinium-thiocyanate. A
first phenol-chloroform-isoamyl alcohol extraction was fol-
lowed by a second extraction, this time using chloroform-isoa-
myl alcohol only, and precipitation of RNA with 2-propanol.
The RNA was then redissolved in lysis buffer, precipitated
again, and recovered by centrifugation. Finally, the pellet was
washed with 80% ethanol. Northern blotting was done accord-
ing to standard procedures [30]. Slot blotting was done as de-
scribed previously [15]. Briefly, RNA samples were serially two-
fold diluted in a solution containing 50 mg/mL yeast tRNA
(Boehringer, Mannheim, Germany). The dilution tubes were
incubated at 65°C for 20 min after addition ofa formaldehyde-
standard saline citrate solution, followed by shock cooling on
ice. The first six dilutions were then blotted on nitrocellulose
membranes (Schleicher & Schuell, Dassel, Germany) using the
minifold II apparatus (Schleicher & Schuell) according to the
manufacturer's protocol. The membranes were hybridized to ra-
diolabeled cDNA probes under standard high-stringency condi-
tions. The MxA probe consisted of the complete coding region
of the MxA cDNA cut from the plasmid BShuMxC4b by EcoRI
digestion [21]. The human {3-actin probe consisted of the com-
plete coding region of the {3-actin cDNA cut from the plasmid
pCDV 1 by BamHI digestion [31]. Both probes were labeled
with [32PJdCTP (Amersham-Buchler, Braunschweig, Germany)
using a nick translation kit (Amersham-Buchler).
ELISA for MxA protein. Protein extracts from pellets of 2.5
X 106 PBMC or whole blood were assayed in a MxA-specific
ELISA exactly as described [32].
Measurement of2-5A synthetase activity. 2-5A synthetase ac-
tivity was measured in extracts from PBMC as described by Buf-
fet-Janvresse et al. [33].
Assays for {3rmicroglobulin and neopterin. {32-microglobulin
and neopterin concentrations in plasma samples were quanti-
tated by commercially available RIAs (Pharmacia, Freiburg,
and Henning, Berlin, respectively).
Results
Yellow fever vaccination. Eleven healthy adults were vac-
cinated with 17-D YFV vaccine strain to produce a self-limit-
ing viral infection. They were studied for MxA gene expres-
sion as a marker for endogenous IFN. One volunteer, who
will be called "patient x," was monitored more closely than
the rest. Clinical signs of infection did not develop, but sero-
conversion occurred in all cases indicating successful vaccina-
tion. Three additional volunteers were vaccinated and served
as negative controls. They had been vaccinated before and
were already immune to YFV.
Serum IFN. Vaccination of nonimmune persons led to a
small increase in serum type I IFN titers that was most pro-
nounced on day 7 after vaccination (table 1). The low IFN
activity measured was barely above the detection limit ofthe
bioassay, yet provided good evidence for systemic infection
with the attenuated virus. In contrast, no increase in IFN
activity was found in the 3 immune controls, indicating ab-
sence of viremia due to neutralization of the vaccine. A
novel sensitive assay specific for biologically active human
type I IFN, the MxR assay, has been described by Lleonart et
al. [28]. This assay makes use of the IFN-responsive murine
Mx I promoter, which is similar to the human MxA promoter
[34]. It discriminates against IFN-)' and other cytokines and
lID] 994; 169 (April) MxA Induced by Yellow Fever Virus Vaccine 809
Table 1. Serum type I interferon (units/ml.) after yellow fever virus vaccination.
Immune
Healthy non immune persons controls
Days after
vaccination 2 3 4 5 6 7 8 9 10 II 12 13
0 <6 <3 <18 <6 <6 <6 <6 <6 <3 <9 <6 6 <6
3 <6 <3 <18 6 <6 NO NO NO ND ND NO 6 <6
5 15 6 <18 9 <6 <6 NO NO ND ND NO 6 <6
7 9 6 <18 18 9 18 9 9 9 18 <6 6 <6
II <6 <3 <18 <6 <6 <6 NO NO NO NO <6 6 <6
NOTE. Serum samples were obtained at times after vaccination indicated and assayed for interferon activity in plaque-reduction assay as described in
Material and Methods. NO, not done.
thus should provide an excellent test system for MxA-induc-
ing IFN activities in human sera. Indeed, using this assay,
circulating type I IFN could be demonstrated in some of the
serum samples of patient x. The detectable IFN concentra-
tions were low, again barely exceeding the detection limits of
the assay (--2-3 units/ml.; data not shown). An EIA specific
for IFN-a2a failed to detect IFN in any of the samples ana-
lyzed, indicating that this IFN subtype, ifpresent, was below
the detection limit of 0.5 units/rnl, (data not shown).
Kinetics of MxA RNA expression in vivo. To determine
the in vivo kinetics of MxA gene expression, we analyzed
steady-state levels of MxA RNA in PBMC obtained from
patient x by the slot-blotting technique (figure lA). Low ba-
sal levels of MxA transcripts were detectable in the prevac-
cination sample, as described previously [21]. The intensity
of the MxA signal did not change significantly during the
first 24 h after vaccination. An increase in MxA signal inten-
sity was clearly visible 36 h after vaccination. The signal
remained enhanced between days 2 and 7. Steady-state MxA
RNA levels were highest on days 5 and 7 when they were
increased -- 30-fold above day 0 levels. The signal was back
to normal on day 11. Likewise, the MxA gene was regularly
induced in the other 6 nonimmune individuals in which a
pre- and postvaccination sample was analyzed for MxA
RNA, although the extent of induction varied between 8-
and 32-fold. Figure 1B shows results for 3 subjects. Northern
blot analysis showed that the MxA RNA was of the proper
size (data not shown). No induction ofMxA RNA was found
in the immune controls (figure IB).
Kinetics ofMxA protein expression in vivo. Next, intracel-
lular MxA protein concentrations were determined in ali-
quots of the same samples using a recently established MxA
ELISA [32]. Figure 2A shows the results obtained with
PBMC of patient x. MxA protein concentrations were low
before vaccination and remained low for the first 24-30 h
after vaccination. They subsequently increased 70-fold from
20 to 1400 ng/2.5 X 106 cells. This maximum was reached
on day 7 after vaccination. Thereafter, MxA concentrations
decreased slowly and were still elevated threefold on day 19.
The in vivo half-life ofMxA protein was estimated to be --4
days as judged from the decrease of the slope after day 11
when MxA gene expression had virtually stopped. Further-
more, ELISA quantitation of MxA protein was done in
whole blood samples from 10 additional nonimmune volun-
teers (figure 2B). A marked increase in MxA protein concen-
trations, 50-fold on average, was reproducible in all of them.
In contrast, MxA protein content remained at basal levels in
all 3 immune subjects (figure 2C).
Comparison of different markers for IFN action. Several
IFN-inducible genes are activated by type I and type II IFNs.
Their products have previously been used as markers for IFN
[6, 8, 12, 22, 23]. We therefore determined in parallel the
kinetics of the three most widely used IFN markers. Aliquots
ofblood samples from patient x were analyzed for 2-5A syn-
thetase activity, f32-microglobulin, and neopterin (figures 3,
4). There was a rapid increase in 2-5A synthetase activity in
PBMC (~15-fold) during the first 7 days after vaccination.
The increase and decrease of enzyme levels paralleled the
observed changes in MxA protein concentrations (figure
3A). Likewise, an increase in enzyme activity was found in
most of the 10 other nonimmune subjects (figure 3B). How-
ever, there was considerable variability. For example, the
2-5A synthetase activity remained at basal levels in I sub-
ject, although MxA protein concentrations increased from
5.0 to 421.3 ng/mL of blood in aliquots of blood samples
obtained on days 0 and 7, respectively. Moreover, 2 of the 3
immune controls also reacted and showed a 2-5A synthetase
induction similar to that ofnonimmune persons (figure 3C).
Plasma concentrations of f32-microglobulin rose tempo-
rarily after patient x was vaccinated. They exceeded the nor-
mal upper limitof3.0 mg/L on day 7, reaching 3.5 rng/L, but
returned to low levels by day 11 (figure 4A). The plasma
levels of neopterin behaved similarly, increasing about two-
fold, with a peak on day 7 just above the normal upper limit
of 2.5 ng/ml. (figure 4A). Serum f32-microglobulin also in-
creased in all nonimmune subjects tested (figure 4B). With
concentrations remaining within the normal range in most
instances, this increase was modest but significant. No
change was observed in immune controls (figure 4C). Neop-
terin levels were not investigated further.
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Discussion
We compared the usefulness of MxA as a marker for en-
dogenous type I IFN with various classic IFN markers, such
as 2-5A synthetase, .B2-microglobulin, and neopterin, moni-
toring them in parallel during a controlled and self-limiting
viral infection in otherwise healthy adults. Inoculation of
attenuated viruses, such as measles or YFV vaccines, usually
leads to systemic infection and activation of the IFN system
[35.36]. We chose the YFV vaccine, since it is innocuous yet
causes a viremia that occurs uniformly between days 3 and 9
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Figure 2. Kinetics of MxA protein expression in peripheral
blood mononuclear cells (PBMC) during infection in patient x (A).
10 other nonimmune subjects (B). and 3 immune controls (C).
Blood was taken at times after vaccination indicated; MxA protein
was quantitated by ELISA [32] in extracts prepared from PBMC
(2.5 X 106) (A) or whole blood (B, C). Coefficient of variation of
assay. < 10%. In Band C, only peak MxA level after vaccination is
shown for each subject.
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Figure 1. Kinetics of MxA RNA expression in peripheral blood
mononuclear cells (PBMC) during infection (A) in patient x, and
(B) in 3 additional nonimmune subjects. and an immune control
(B). Blood was taken at times after vaccination indicated; PBMC
were isolated by Ficoll-Paque gradient centrifugation. Total cellu-
lar RNA was prepared from PBMC (5 X 106) and serially diluted
2-fold. Dilutions were blotted below each other by slot blotting.
Original undiluted RNA solution was blotted on top. Membrane
was hybridized under standard high-stringency conditions to radio-
labeled MxA cDNA probe [21] or to radiolabeled l1-actin cDNA
probe [31].
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after vaccination with a peak on day 5 [36]. Most adults are
not immune. and infection can easily be demonstrated by an
increase in YFV antibodies. In addition. circulating IFN has
been found in a majority of vaccinated subjects [36].
IFN markers can be meaningfully compared in vaccinees
for three reasons. First. the kinetics of IFN production and
action follows the natural course of infection. Second. the
endogenous IFN released is of natural subtype composition.
This contrasts with the somewhat artificial nature ofprevious
studies in which injection of recombinant IFNs was used to
assess the dynamics of single IFN markers in vivo [12, 23,
24]. Third, previously vaccinated subjects were available
who resisted reinfection due to specific immunity. They
served as appropriate controls. A conventional bioassay
showed low levels of circulating type I IFN in most nonim-
mune vaccinees but not in similarly vaccinated immune con-
trols. In patient x, biologically active type I IFN was detected
at very low concentrations by the MxR assay in only some of
the serum samples obtained [28]. Because of the short half-
life of IFN, serum levels are low in many patients with acute
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150 --------------------..., no refractory phase but can be repeatedly restimulated by
IFN [41], these findings indicate that type I IFN production
probably ceased between days 7 and 11 after vaccination.
Low MxA RNA levels were found in PBMC of all healthy
persons studied [21,22] (unpublished data) and can be attrib-
uted to the action ofsmall amounts ofconstitutive IFN [40].
The MxA protein response was even more striking. The in
vivo kinetics of MxA protein accumulation were docu-
mented using a newly developed ELISA [32]. This assay al-
lowed quantitation of MxA concentrations in PBMC and
showed that the protein rose r-: 50-fold above prevaccination
levels. More importantly, the decay in MxA protein levels
was remarkably slow and MxA protein concentrations were
still elevated 19 days after vaccination. MxA protein is
known to be quite stable in cells [22, 32, 41]. Its half-life in
in vitro IFN-treated PBMC has been estimated to be several
days [22, 32]. Ronni et al. [41] recently reported the half-life
of MxA protein to be 2.3 days. The situation in vivo is, of
course, more complex. During infection, endogenous IFN is
produced as a consequence of successive viral replication
and may be present in varying concentrations for prolonged
periods. By necessity, different blood samples were analyzed
at each time point. Under these circumstances, MxA protein
in PBMC had a half-life of......,4 days in vivo as estimated from
the decrease in MxA protein concentrations after day II (fig-
ure 2A) when MxA gene activity was already back to normal
(figure lA). The relatively long half-life makes MxA protein
a useful marker for detecting even small amounts ofendoge-
nous IFN. If IFN is released continuously for some time,
MxA protein will gradually accumulate in PBMC and indi-
cate the presence of biologically active IFN that may other-
wise escape direct measurement. If IFN is released over a
short period but in sufficient quantity to activate MxA, a
single IFN pulse will still be detectable even days later. In
both cases, MxA protein will be a good indicator of recent
type I IFN activity in vivo. To differentiate between past and
present in vivo IFN effects more precisely, MxA mRNA
pools in PBMC should be analyzed. Basal levels are con-
stantly low since the MxA gene is silent in the absence of
type I IFN [15, 16, 21, 22]. As shown here, gene activation in
vivo is fast and short lived. Hence, monitoring of MxA
mRNA allows detection of sudden changes in IFN activity
while measuring MxA protein is more suitable for recording
long-term changes.
Among the various IFN markers, 2-5A synthetase has
been used the most. Increased enzyme activity has been dem-
onstrated in PBMC of patients with naturally occurring viral
diseases [6]. In our experimentally infected individuals, 2-5A
synthetase and MxA protein showed similar expression ki-
netics. The main difference is that the MxA gene in PBMC
responds exclusively to type I IFN [15, 16], whereas the
2-5A system is activated by both type I and type II IFN [7].
Of interest, there was an induction of2-5A synthetase activ-
ity in 2 of the 3 immune controls. Since no activation of the
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Figure 3. Kinetics of 2'-5'-0Iigoadenylate (2-5A) synthetase ac-
tivities in peripheral blood mononuclear cells (PBMC) during in-
fection in patient x (A), 10 additional nonimmune subjects (B),
and 3 immune controls (C). Blood was taken at times after vaccina-
tion indicated, and 2-5A synthetase activity was determined in ex-
tracts of2.5 X 106 PBMC. In A, day 5 sample was not available for
2-5A synthetase assay. In Band C, only peak activity after vaccina-
tion is shown for each subject.
viral diseases [4, 37]. Fluctuations are caused by continuous
production and clearance of IFN.
MxA gene expression could readily be demonstrated in
blood cells ofall nonimmune volunteers, indicating the cells
had been exposed to type I IFN and were responding to it. As
expected, no MxA gene activation occurred in immune con-
trols. We have previously shown that enhanced MxA tran-
scription occurs in PBMC within 90 min of a subcutaneous
injection of IFN-a into healthy persons [38]. We therefore
assume that the increased MxA transcript levels observed
after vaccination reflected the appearance of endogenous
type I IFN. The remote possibility that viral replication di-
rectly activated MxA gene expression is unlikely given the
strong induction observed but cannot formally be excluded.
We previously showed that the human MxA gene shows al-
most no primary response to RNA viruses that are otherwise
good inducers of IFN [39]. MxA RNA levels rapidly re-
turned to prevaccination levels, reflecting the short half-life
of MxA transcripts [38]. Since MxA gene expression shows
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Figure 4. Kinetics of ~2-microglobulin
and neopterin serum levels during infection
in patient x (A). Coefficients of variation
were <5% in both assays.Changes in plasma
~2-microglobulin levels are shown in 10 ad-
ditional nonimmune subjects (B) and in 3
immune controls (C). Dashed lines, normal
upper and lower limits of ~2-microglobulin
serum concentrations. Increase in .B2-micro-
globulin serum concentrations on day 7 after
vaccination vs. day 0 was significant in the
II nonimmune volunteers as estimated by t
test for paired samples (a = .00I,f= 10).
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MxA gene was found in these subjects, the induction of the
2-5A system was most likely due to the effect of type II IFN
or other cytokines generated during the immune response
initiated by revaccination. Therefore, if effects of type IIFNs
are to be differentiated from those of IFN-')' or other cyto-
kines in vivo, the MxA assay should be used preferentially.
Neopterin and fJ2-microglobulin are nonspecific [13, 14] and
reacted poorly in our analysis.
The MxA protein has successfully been used as a clinical
marker in patients treated with recombinant IFN-a [23, 24]
and in patients with diseases in which acid-labile serum IFN-
a seems to playa role [42, 43], such as in those with symp-
tomatic human immunodeficiency virus type I infection
[25] or systemic lupus erythematosus [26]. The present re-
sults indicate that MxA gene expression in PBMC is promi-
nent during an acute viral infection and is a sufficiently sen-
sitive marker to reveal the transient production of very low
levels of endogenous IFN that are otherwise barely detect-
able. Because of their specificity for type I IFN, MxA assays
may be most helpful in evaluating diseases with suspected
viral etiology and, perhaps, subclinical viral infections or
virus carriers. The novel MxA ELISA used here facilitates
the handling of large numbers of clinical samples. Monitor-
ing MxA expression could, therefore, become a useful diag-
nostic tool for detecting even minute quantities of type I IFN.
Acknowledgments
We thank Charles Weissmann, University ofZiirich, for pro-
viding Vero-Mx 13 cells; Herbert Schmitz, University of Ham-
burg, for determining anti-yellow fever virus antibodies; Harry
Towbin, CIBA GEIGY, Basel, for determining MxA protein in
whole blood; Ursula Elsasser, University of Freiburg, for IFN
immunoassays; and Jiirg Fah and Peter Staeheli for help and
valuable suggestions.
References
1. Staeheli P. Interferon induced proteins and the antiviral state. Adv
Virus Res 1990;38: 147-200.
2. Baron S, Coppenhaver DH, Dianzani F, et al. Interferon principles and
medical applications. Galveston, TX: University of Texas Medical
Branch, 1992.
3. Hill DA, Walsh JH, Purcell RH. Failure to demonstrate circulating
interferon during incubation period and acute stage of transfusion
associated hepatitis. Proc Soc Exp Bioi Med 1971;136:853-6.
4. Pirovino M, Aguet M, Huber M, et al. Absence of detectable serum
interferon in acute and chronic viral hepatitis. Hepatology
1986;6:645-9.
5. Thomas He Pignatelli M, Scully LJ. Viruses and immune reactions in
the liver. Scand J Gastroenterol Suppl 1985;114:105-17.
6. Schattner A, Wallach D, Merlin G, Hahn T, Levin S, Revel M. Assay of
an interferon-induced enzyme in white blood cells as a diagnostic aid
in viral diseases. Lancet 1981 ;2:497.
7. Witt PL, Spear GT, Helgeson DO, Lindstrom LJ, Smalley RV, Borden
EC. Basal and interferon-induced 2',5'-oligoadenylate synthetase in
human monocytes, lymphocytes, and peritoneal macrophages. J In-
terferon Res 1990; 10:39 3-402.
8. Lodemann E, Kornhuber B, Gerein V, von Ilberg C. (2'-5')0Iigo(A)
synthetase as a monitor of interferon action in juvenile laryngeal
papillomatosis. J Interferon Res 1984;4:283-90.
9. Schattner A, Merlin G, Wallach D. Monitoring ofinterferon therapy by
assay of (2'-5')0Iigo-isoadenylate synthetase in human peripheral
white blood cells. J Interferon Res 1981; I:587-94.
10. Buffet-Janvresse C, Vannier JP, Laurent AG, Robert N, Hovanessian
AG. Enhanced levels of double-stranded RNA-dependent protein
kinase in peripheral blood mononuclear cells of patients with viral
infections. J Interferon Res 1986;6:85-96.
II. Carlin JM, Borden EC, Byrne GI. Enhancement of indoleamine 2,3-
dioxygenase activity in cancer patients receiving interferon-boer' J
Interferon Res 1989;9: 167-73.
JID 1994;169 (April) MxA Induced by Yellow Fever Virus Vaccine 813
12. Cheng YSE, Becker-Manley MF, Rucker RG, Borden EC. Accumula-
tion of guanylate binding proteins in patients treated with interfer-
ons. J Interferon Res 1988;8:385-91.
13. Erwin PE, Wibell L. Serum t12-microglobulin in various disorders. Clin
Chim Acta 1973;43: 183-7.
14. Magreiter T, Fuchs D, Hausen A, et al. Neopterin as a new biochemical
marker for diagnosis of allograft rejection. Transplantation
1983;36:650-3.
15. Simon A, Fiih J. Haller O. Staeheli P. Interferon-regulated Mx genes are
not responsive to interleukin-I, tumor necrosis factor, and other cy-
tokines. J Virol 1991;65:968-71.
16. von Wussow P. Jakschies D, Hochkeppel HK, Fibich C, Penner L,
Deicher H. The human intracellular Mx-homologous protein is spe-
cifically induced by type I interferons. Eur J Immunol 1990;20:
2015-9.
17. Horisberger MA. Interferon-induced human protein MxA is a GTPase
which binds transiently to cellular proteins. J Virol 1992;66:4705-9.
18. Pavlovic J. Zurcher T, Haller 0, Staeheli P. Resistance to influenza
virus and vesicular stomatitis virus conferred by expression ofhuman
MxA protein. J Virol 1990;64:3370-5.
19. Staeheli P, Pitossi F, Pavlovic J. Mx proteins: GTPases with antiviral
activity. Trends Cell Bioi 1993;3:268-72.
20. Schnorr JJ, Schneider-Schaulies S. Simon-Jodicke A, Pavlovic J, Horis-
berger MA, ter Meulen V. MxA-dependent inhibition of measles
virus glycoprotein synthesis in a stably transfected human monocytic
cell line. J Virol 1993;67:4760-8.
21. Aebi M, Fah J, Hurt N. et al. cDNA structures and regulation of two
interferon induced Mx proteins. Mol Cell BioI 1989;9:5062-72.
22. Goetschy JF. Zeller H, Content J, Horisberger MA. Regulation of the
interferon-inducible IFt-78K gene, the human equivalent of the mu-
rine Mx gene. by interferons, double-stranded RNA, certain cyto-
kines, and viruses. J Virol 1989;63:2616-22.
23. Jakschies D, Hochkeppel HK, Horisberger MA, Deicher H, von Wus-
sow P. Correlation of the antiproliferative effect and the Mx-homolo-
gous protein induction by interferon in patients with malignant mela-
noma. J Invest Derrnatol 1990;95:238S-41 S.
24. Jakschies 0, Hochkeppel HK, Horisberger MA, Deicher H. von Wus-
sow P. Emergence and decay of the human Mx homolog in cancer
patients during and after interferon-a therapy. J BioI Response Mod
1990;9:305-12.
25. von Wussow P, Jakschies D, Block B. The interferon-induced Mx-ho-
mologous protein in people with symptomatic HIV -I infection.
AIDS 1990;4: 119-24.
26. von Wussow P, Jakschies 0, Hochkeppel HK, Horisberger MA, Har-
tung K, Deicher H. Mx homologous protein in mononuclear cells
from patients with systemic lupus erythematosus. Arthritis Rheum
1989;32:914-8.
27. Rubinstein S, Familletti p. Pestka S. Convenient assay for interferons. J
ViroI1981;37:755-8.
28. Lleonart R. Niif D, Browning H, Weissmann C. A novel, quantitative
bioassay for type I interferon using a recombinant indicator cell line.
Bio/Technology 1990;8: 1263-7.
29. Chomcynski P, Sacchi N. Single step method of RNA isolation by acid
guanidinium thiocyanate-phenol-chloroform extraction. Anal Bio-
chern 1987;162:156-9.
30. Staeheli P, Danielson P, Haller 0, Sutcliffe JG. Transcriptional activa-
tion of the mouse Mx gene by type I interferon. Mol Cell BioI
1986;6:4470-4.
31. Gunning P, Ponte P. Okayama H, Engel J. Blau H. Kedes L. Isolation
and characterization of full length cDNA clones for human a, t1 and
'"Y actin mRNAs. Mol Cell Bioi 1983;3:787-95.
32. Towbin H, Schmitz A. Jakschies D. von Wussow P, Horisberger MA. A
whole blood immunoassay for the interferon inducible human Mx-
protein. J Interferon Res 1992; 12:67.
33. Buffet-Janvresse C, Magard H, Robert N, Hovanessian AG. Assay and
the levels of 2-5A synthetase in lymphocytes of patients with viral.
bacterial and autoimmune diseases. Annals Immunol (lnst Pasteur)
1983; 1340:247-58.
34. Chang KC, Hansen E, Foroni L, Lida J, Goldspink G. Molecular and
functional analysis of the virus- and interferon-inducible MxA pro-
moter. Arch Virol 1991;117:1-15.
35. Petralli JK, Merigan TC, Wilbur JR. Circulating interferon after
measles vaccination. N Engl J Med 1965;273: 198.
36. Wheelock EF, Sibley WA. Circulating virus, interferon and antibody
after vaccination with the 17-0 strain ofyellow-fever virus. N Engl J
Med 1965;273: 194-8.
37. Parry RP, Parry JV. Interferon assay as a diagnostic test. Lancet
1981; I :506-7.
38. Fah J, Staeheli P, Haller O. Akkumulation von Mx mRNA als Mad filr
die biologische Wirksamkeit von Interferon. In: Niederle N, von
Wussow P. Interferone, praklinische und klinische Befunde. Berlin:
Springer-Verlag, 1990: 122-36.
39. Bazzigher L, Pavlovic J, Haller O. Staeheli P. Mx genes show weaker
primary response to virus than other interferon-regulated genes. Vi-
rology 1992; 186: 154-60.
40. Tovey MG, Streuli M. Gresser I, et al. Interferon messenger RNA is
produced constitutively in the organs of normal individuals. Proc
Natl Acad Sci USA 1987;84:5038-42.
41. Ronni T, Melen K. Malygin A. Julkunen I. Control ofIFN-inducible
MxA gene expression in human cells. J Immunol 1993; 150: 17/5-
26.
42. Eyster ME, Goedert JJ, Poon MC, Preble OT. Acid-labile alpha inter-
feron, a possible preclinical marker for the acquired immunodefi-
ciency syndrome in hemophilia. N Engl J Med 1983;309:583-6.
43. Preble OT. Black RJ. Friedmann RM. Klippel JH. Vilcek J. Systemic
lupus erythematosus: presence in human serum of an unusual acid
labile leukocyte interferon. Science 1982;2 I6:429-31.
